Advertisement
Advertisement
KYTX
Kyverna Therapeutics, Inc. Common Stock
8.02
USDSponsored
-0.01
-0.07%
Mar 27, 09:35 UTC -4
Open
KYTX Earnings Reports
Positive Surprise Ratio
KYTX beat 5 of 8 last estimates.
63%
Next Report
Next Week
Date of Next Report
Apr 01, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.87
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 24 (Revenue/ EPS)
--
/-1.14%
Kyverna Therapeutics, Inc. Common Stock earnings per share and revenue
On --, KYTX reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.87 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were Kyverna Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q-- --?
For Q-- --, Kyverna Therapeutics, Inc. Common Stock reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
How did the market react to Kyverna Therapeutics, Inc. Common Stock's Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Kyverna Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Apr 01, 2026.
What are the forecasts for Kyverna Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, Kyverna Therapeutics, Inc. Common Stock is expected to report EPS of -$0.87 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement